India, April 25 -- image credit- shutterstock

According to the Grant Thornton Bharat Pharma & Healthcare Dealtracker, Q1 2025 recorded 71 deals amounting to $2.6 billion, reflecting a slight 5% dip in volumes and a significant 69% drop in values compared to Q4 2024.

Despite the moderation in deal values, investor interest in the healthcare and pharmaceutical sector remains resilient. M&A activity contributed 57% of the total deal value, while private equity drove 59% of the overall volume.

Excluding IPOs and QIPs, the quarter saw 67 deals valued at $2.1 billion-a marginal 3% decline in volumes and a 70% drop in values, primarily due to the absence of the $5 billion Aster DM Healthcare-Quality Care India merger that skewed the previous ...